Teva to Host a Conference Call to Discuss Second Quarter 2022 Financial Results at 8:00 a.m. ET on July 27, 2022


TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will host a conference call and live webcast the same day at 8:00 a.m. ET.

To participate, please register in advance. here for a local or toll-free phone number and your personal PIN.

A live webcast of the call will be available on Teva’s website at:

After the call concludes, a replay of the webcast will be available within 24 hours on Teva’s website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio of over 3,500 products in nearly every therapeutic area. Around 200 million people worldwide take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations that support our growing portfolio of specialty and biopharmaceutical products. Learn more about

Caution Regarding Forward-Looking Statements

This document and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on the current beliefs and expectations of management and are subject to substantial risks and uncertainties, known and unknown, which could cause our future results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to compete in the marketplace; our substantial indebtedness; our business and operations generally, including: uncertainty regarding the COVID-19 pandemic and governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2022 and our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Factors of risk “. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to place undue reliance on these forward-looking statements.


Comments are closed.